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After failed attempts at producing bacteria-based vaccines, the discovery of a viral agent
causing yellow fever and its isolation in monkeys opened new avenues of research. Subse-
quent advances were the attenuation of the virus in mice and later in tissue culture; the cre-
ation of the seed lot system to avoid spontaneous mutations; the ability to produce the
vaccine on a large scale in eggs; and the removal of dangerous contaminants.An important
person in the story is Max Theiler, who was Professor of Epidemiology and Public Health at
Yale from 1964-67, and whose work on virus attenuation created the modern vaccine and
earned him the Nobel Prize.
At the close of the 19th century, yellow
fever was a known and feared pestilence of
the western hemisphere and the coastal re-
gions ofWestAfrica, for which no cause or
effective treatment was known. Known
often as “yellow jack” because of the yel-
low quarantine flag on ships, the disease
terrorized populations and severely dis-
rupted trade. Though the medical profes-
sion was still in the dark on many aspects
of the illness, accumulated observations
had rendered certain facts clear: It occurred
in epidemic and endemic form; it was as-
sociated with ports, and new outbreaks
were often associated with the arrival of a
ship from a known focus; a transmittable
“germ” was presumed, but transmission
was not direct; and recovery from the dis-
ease conferred durable immunity [1].
Patrick Manson, in his tropical medicine
text of 1898, referred only to a “germ or
virus,” though noting that it probably re-
quired an interval of time outside the body
to render it infectious [2].
The close of the 19th century also wit-
nessed dramatic discoveries in the new sci-
ence of bacteriology that would transform
medicine forever. Several investigators
claimed to have found bacteria responsible
for yellow fever, and the first “vaccines”
were created from these candidates. Be-
cause of alleged successes, Dr. George
Sternberg, an army doctor often called the
“father ofAmerican bacteriology,” was ap-
pointed by President Grover Cleveland to
investigate. His thorough study found the
vaccines poorly conceived or ineffective
[1], so that by the turn of the century there
was essentially no progress in yellow fever
prevention.
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After the Spanish-American War, yel-
low fever in the notoriously endemic Cuba
became a particularly American concern.
Sanitation measures in Havana (i.e., elimi-
nating the “miasmas” with sewage disposal,
clean water, and overall cleanliness) failed
to curb the rising incidence. Consequently,
Sternberg, as U.S. surgeon general, ap-
pointed aYellow Fever Commission, headed
by Walter Reed, to investigate. This famous
commission, through careful experiments,
established that mosquitoes transmitted the
disease and the agent was filterable through
a Berkefeld filter, excluding a bacterial
agent [3,4]. Bacteria-based vaccines quickly
became extinct. Many attempts to infect lab-
oratory animals failed, however, leaving the
scientific community without a laboratory
model. An attempt to bypass this difficulty
was made in 1901, when Dr. John Guiteras,
based in Havana, noted the low mortality in
the Walter Reed experiments (14 inocula-
tions and no deaths) and attempted to immu-
nize subjects with a tiny dose (one to four
mosquito bites each) of live agent. Unfortu-
nately eight out of 42 volunteers became ill,
and three died [5]. Further work on immu-
nization came to a halt, and most attention
henceforth focused on prevention through
mosquito control.
When the Panama Canal opened in
1912, large “unseasoned” populations
around the world were suddenly liable to ex-
posure. The Rockefeller Foundation’s Inter-
national Health Commission resolved to
assist in yellow fever eradication, and in
1918, a team was dispatched to Guayaquil,
Ecuador,aresidualendemiccenter,toimple-
ment control measures. The team included
Hideyo Noguchi. Noguchi, born in Japan,
had risen from extreme poverty to earn a
medical degree and eventually a position at
theRockefellerInstitute.Healreadyhaddis-
tinguished himself by the discovery of spiro-
chetes in brain tissue of paretics. Noguchi
was aware of another spirochete, Leptospira
icterohemorrhagiae, as the cause of Weil’s
disease. There was speculation that Weil’s
disease and yellow fever might be identical
or closely related diseases, and Noguchi
sought spirochetes in Ecuador. He found
some in the livers of “yellow fever” patients
and was able to pass them easily to guinea
pigs. He felt he had discovered the causative
agent of yellow fever and strongly implied
thisinseveralpublications[6,7,8].Henamed
thenewspirocheteLeptospiraicteroides and
claimed to be able to distinguish it serologi-
cally from L. icterohemorrhagicae [9]. In
short order, he produced a vaccine and anti-
serum against yellow fever, both manufac-
tured at the Rockefeller Institute, and used
quite extensively in the United States, Latin
America, and French African colonies [10].
The vaccine also was available in NewYork
City for travelers (the first travel medicine
clinic?) [11]. Noguchi published “success-
ful” results on 7,964 vaccinations [12,13].
But seasoned investigators could not dupli-
cate his results, and doubts grew [14]. The
sloppy statistics of the vaccine trials, the es-
tablished easy filterability of the causative
agent,andtheinabilityofotherstoinfectlab-
oratory animals were facts that Noguchi
could not explain away [15].
Then, in 1926, Max Theiler, born in
South Africa and son of a veterinarian, and
Andrew Watson Sellards showed that the L.
icteroides obtained from Noguchi was sero-
logically identical with L. icterhemorrhag-
ica [16]. In that same year, the Rockefeller
Foundation quietly discontinued its distribu-
tion of the vaccine, and there was no alter-
nate candidate.
AFRICA ACTIVITIES, ISOLATION OF
VIRUS, AND A NEW HOST
After World War I, the Rockefeller
Foundation expanded its yellow fever activ-
ities toAfrica.The secondWestAfricanYel-
low Fever Commission was formed in 1925
(a prior commission in 1920 had accom-
plished little). The tense and tragic story of
this expedition has been told many times
[17,18,19,20], and only brief comments will
be made here. The expedition, based near
Lagos, was to determine whether African
yellow fever was the same as yellow fever in
South America, to find the causative agent
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and to study its epidemiology. Major Henry
Beeuwkes, a Hopkins-trained bacteriologist
retired from the army, led the expedition. He
was joined by Adrian Stokes, a London-
based professor of pathology who was an
expert on leptospirosis, and others.
In June 1927, blood from a 28-year-old
African named Asibi suffering from a rela-
tivelymildfebrileillness,whichhesurvived,
wasinjectedintoaMacacusrhesusimported
fromIndia(Africanmonkeysdidnotbecome
ill). The monkey proved susceptible, estab-
lishing the infection for the first time in a
suitablelaboratoryhost[21].Tragically,after
only a brief interval to savor this discovery,
Stokes perished from yellow fever, the first
victim of the expedition. Noguchi arrived in
Novembertoaidintheresearch,tryingagain
to verify his leptospira theory, which Stokes
already had investigated with negative re-
sults. His laboratory was described as being
inastateofconfusionandhistechniquehap-
hazard. He was careless about labeling and
screening, secretive in his behavior, and a
source of tension to a group already stressed
by the primitive conditions and the mortal
danger of the work. He infected an astound-
ing 1,200 monkeys, but found no leptospira.
With the inevitability of a Greek tragedy,
Noguchi, doggedly pursuing his mistaken
idea,eventuallycontractedyellowfever,per-
ishing in May 1928. A third investigator,
William Young, who had performed
Noguchi’s autopsy, also succumbed to yel-
low fever. The expedition was a costly one.
However, the virus now could be re-
moved to the laboratory and properly stud-
ied. In short order, it was shown that serum
from immune humans protected monkeys
against infection, immune serum from South
America protected against theAfrican virus
(thus suggesting that one vaccine would
offer protection globally) [22], and killed
virus would not confer immunity.
At the same time that the West African
Commission was active, Sellards, from the
department of tropical medicine at Harvard,
was on his way to Dakar, Senegal, to study a
yellow fever outbreak when he heard of the
success establishing the virus in rhesus mon-
keys. He joined up with ConstantMathis, di-
rector of the local Pasteur Institute, and Jean
Laigret, who was in charge of the “defense
sanitaire” established in Dakar to cope with
the outbreak. One day, Laigret noticed that
thesonofawomanwithyellowfeverdidnot
appear for his daily visit at the hospital. He
visited the house of this man, Francois May-
ali, and found him with a fever.Asample of
Mayali’sbloodproducedsevereyellowfever
in a rhesus monkey, though Mayali suffered
only a relativelymild case [23,24]. (He lived
to age 62, when he died of a bronchogenic
carcinoma [25].) This virus became known
asthe“Frenchstrain”(theotherremainedthe
“Asibi”strain).TheSellardsteamdiscovered
that the virus survived freezing, allowing
transport of infected liver tissue (instead of
monkeys) for further passage [26].
Initially, some crude vaccines using for-
malin and phenol-preserved liver tissue were
made, with uncertain results [27]. Clearly, a
form of attenuated live vaccine, as well as a
more affordable laboratory host, were
needed. Theiler found a better host.
Theiler was aware that herpes simplex
virus recently had been grown in mouse
brain by Howard Andervont [28], and he
knew about Pasteur’s method of attenuating
rabies virus in non-host nervous tissue.With
this knowledge, Theiler inoculated mice in-
tracerebrally and found that the virus grew
well. More important, with multiple pas-
sages, while there was an increase in neu-
rotropism, there was diminished hepatic
damage and systemic illness (“viscerotro-
pism”) when given back to rhesus monkeys
[29].Thefirstattenuatedstrainhadbeencre-
ated,albeitonewithincreasedneurotropism.
Incidentally, at about the 30th mouse pas-
sage,Theiler contracted yellow fever. Fortu-
nately for posterity, it was a light case.
COMPETING VACCINES
Meanwhile, in New York, the Interna-
tional Health Division (IHD†) of the Rock-
efeller Institute was seeking laboratory
facilities to continue its yellow fever work.
Simon Flexner, director of the Institute, re-
membering that three Rockefeller re-
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fever, hesitantly granted limited space pro-
vided that strict isolation policies were fol-
lowed [30]. Wilbur Sawyer was appointed
to head the new laboratory, andTheiler, after
publishing his work on mouse brain adapta-
tion, left Harvard to join the team.
To emphasize the hazardous nature of
yellow fever work, the IHD in 1931 reported
on 32 cases acquired in eight laboratories
with five deaths [31]. The need for a vaccine
to protect laboratory and field workers was
urgent, and in the same year, the attenuated
butneurotropicFrenchstrain,passagedmore
than 100 times in mouse brain, was given a
trial.Becauseofconcernoverinducinganen-
cephalitis, the virus was combined with im-
munehumanserumobtainedfromrecovered
laboratory staff [32,33]. The first test subject
for this vaccine/serum combination was Dr.
Bruce Wilson of the IHD, on leave from
Brazil and as yet not immune to the disease.
Hewashospitalizedunderstrictisolation,but
there was no reaction beyond some redness
andswellingattheinjectionsite[30,34].Oth-
ers were then successfully vaccinated, and
seraobtainedaftervaccinationprotectedmice
against infection. This “mouse protection
test,” devised byTheiler, was used with vari-
ations as a measure of immunity until after
World War II [35]. The mouse brain-derived
vaccine, given with immune serum, became
the standard vaccine used by the Rockefeller
Foundation for some time.
Meanwhile,acrosstheocean,Laigrethad
been transferred to the Pasteur Institute in
Tunis, then under the direction of Charles
Nicolle,winnerofthe1928NobelPrizeforhis
discovery of the louse transmission of epi-
demic typhus. Sellards and Laigret were anx-
ious to try the mouse brain vaccine there.
Nicolle was hesitant, concerned about intro-
ducinganewvirustoTunis,butagreedtotrials
if conducted in winter when mosquitoes were
rare [36]. The two investigators prepared a
vaccine from mouse brain cultures of the
French strain just as Theiler had done, but
without human serum. Because systemic and
neurologic reactions were sometimes severe,
an attempt was made to “attenuate” the virus.
Initially,athree-doseregimenwastried,using
virus dried for varying periods of time, with
both systemic and neurologic reactions being
noted [23,37,38]. The next technique was to
coatthevirusparticleswithoiloreggyolkand
freeze-drythemixture,creatingafinepowder
of coated virus particles (allegedly allowing a
slow release of virus) that could be reconsti-
tuted in saline on site and given as a single
dose[39].Finally,theteamshowedthatgiving
thislattervaccinebyscarificationproducedan
immunity equivalent to injection, leading to
the use of a combined smallpox-yellow fever
vaccine [40]. The British had opted for the
Rockefellerapproach,vaccinecombinedwith
immune serum.
This state of affairs ― the Rockefeller
Foundation vaccine being used in the West-
ernHemisphere andEnglandandthePasteur
Instituteone-dosevaccine(usuallycombined
with smallpox) being used in France and its
Africancolonies―persistedforsomeyears.
The Rockefeller vaccine appeared safer, but
large amounts of serum were needed, limit-
ing its use on a large scale (attempts to use
animal serum resulted in cases of anaphy-
laxis and were abandoned). The French vac-
cine risked febrile and CNS reactions but
could be used in large campaigns. Using
scarification, one could vaccinate up to 800
people per hour, or about 5,000 per day. By
the end of 1945, about 16 million Africans
had been vaccinated, in spite of the disrup-
tions of the war [41], and 56 million by 1953
[42]. A policy of vaccinating entire popula-
tions at four-year intervals was adopted. In
contrasttoearlierexperience,neurologicside
effects were stated to be rare [43], possibly
because of further virus attenuation (the
number of passages had almost doubled
[44]).Alternatively, surveillance for delayed
reactions may not have been complete, and
detailedfollow-upstatisticsarenotavailable.
BREAKTHROUGHS AND
COMPLICATIONS
In New York, the fear of neurologic re-
actions to the vaccine was still a major con-
cern. Tissue culture techniques, born at the
Rockefeller Institute in the 1920s, might
offer a way out. In 1932, Theiler and Eugen
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fever virus in both mouse and chicken em-
bryo tissue. But extensive passages of both
theAsibi and the French strains failed to af-
fect their neurotropic tendency, so a strategy
of dissecting out the nervous tissue from the
chick embryos was adopted. Eventually, at
the 100th subculture of the Asibi strain in
nervous tissue-deprived embryo (176th in
chick embryo altogether), Hugh Smith,
working with Theiler, noted that the virus
failed to kill mice when injected intracere-
brally ― the “acid test.” Attempts to repeat
the phenomenon with unpassaged virus
failed, suggesting that the attenuation was
due to chance mutations, and more than 100
subcultures of the French strain under the
same conditions showed no loss of neurotro-
pism [45].Animal testing showed the atten-
uated mutant to be safe and immunizing
[46].This breakthrough, because of a chance
mutation, resulted in a strain that appeared
to be sufficiently attenuated to use without
protective immune serum [47]. It was given
the name 17D.
At this point, field testing and prepara-
tions for large scale manufacturing of vac-
cine were in order. In 1937, Hugh Smith
began the project in Brazil (a 13-day sea
voyage at that time). By this time, the jungle
cycle of yellow fever had been recognized
and the goals of vaccination altered to con-
taining the disease rather than eliminating it.
The newly invented techniques of culturing
virus in embryonated eggs and freeze drying
were now available and utilized.Within one
year, 59,000 people were vaccinated with
the 17D strain without severe complications.
By June 1939, the number was up to 1.3 mil-
lion people, without further problems. Smith
moved on to Colombia, where he initiated
another successful program [48]. The way
seemed clear.
However, new and instructive problems
arose. In July 1941, 119 cases of encephalitis
were noted in Brazil, all recipients of one lot
ofvaccineseparatedfromtheparentstrainby
onlyasmallnumberofsubcultures.Thecon-
clusion was that there had been an unfavor-
able mutation during these subcultures, and
thuswasbornthe“seedlot”system,whereby
“masterseeds”arecreatedfromparentstrains
and kept frozen for future use, consequently
eliminating extra subcultures [49].
Simultaneously, another complication
was emerging. Starting in 1937, cases of de-
layed jaundice, sometimes clustered, were
noted in England and Brazil [50,51]. Serum
was suspected as the source [52]. Because
the virus was unstable in water and saline, a
small amount of human serum had been
used as a protein source to provide stabiliza-
tion during filtration. The use of serum was
abandoned in Brazil, aided by sterile tech-
niques to avoid filtration, and no further
cases occurred. But this complication would
appear again elsewhere.
The outbreak of World War II created
new and huge demands for vaccine.An epi-
demic of yellow fever near the North
AfricanWar zones early in the conflict made
clear the vulnerability of the troops. In the
United States, the vaccine was given to vir-
tually all recruits. Between January 1941
andApril 10, 1942, an astounding 7 million
doses were distributed, all manufactured by
the International Health Division of the
Rockefeller Institute, at no charge. A strain
in use in Colombia was employed, since
more than 600,000 doses had been given
there without serious complications, but
with serum still used as a stabilizer. Eventu-
ally, 26,771 cases of jaundice, occurring 60
to 150 days after vaccination, were reported
in U.S. personnel [53], and thousands more
almost certainly occurred [54]. General
Joseph Stilwell was among them [55].There
was a mortality of about three per 1,000
cases (the outbreak was later shown to be
due to hepatitis B).The response of the press
was generally quiet, perhaps recognizing the
exigencies of war, but the Chicago Tribune
reacted with some outrage, noting that 20
times as many soldiers had fallen victim to
the vaccine as had been wounded thus far in
the war. The paper called for an investiga-
tion, claiming inadequate testing and ques-
tioning the need for all soldiers to receive
the vaccine [56].
There was indeed a comprehensive in-
vestigation. Almost all cases had received
vaccine from a limited number of lots, and
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culprit.Aconscious decision to use serum as
a stabilizing agent had been made on the
grounds that the link between serum and
jaundice was not fully established and there
was too little experience using vaccine with-
out serum stabilization to recommend it on
so large a scale. The high demand for vac-
cine required a weekly supply of eight to 10
liters of pooled serum, and procurement of
serum was the limiting factor in production.
Most of it was obtained from the Johns Hop-
kins School of Public Health, the donors
being medical students, interns, nurses, and
medical technologists, all presumed healthy.
Later study of donors revealed that several
had prior histories of jaundice. The amount
of serum in a single dose of vaccine was
0.04cc, and the infecting dose in pooled
serum would have been much lower [57].
The immediate action taken was
twofold: Switch to a vaccine without serum,
and restrict vaccination to personnel going
to or through defined areas of yellow fever
risk. These measures resolved the problem,
and the overall experience proved helpful in
the eventual clarification of the two main
types of “infectious” hepatitis. An interest-
ing 50-year follow-up study was conducted
on affected vaccinees, showing a slight in-
crease in incidence of hepatocellular carci-
noma in the non-jaundiced cases only and
no increased mortality from nonalcoholic
liver disease in the entire group [58].
FINAL STEPS
At the end of World War II and in the
years following, the 17D and French vac-
cines were in use on a large scale.As the war
progressed, discussion arose regarding
adoption of international vaccine standards
as a way to avoid quarantine.At the 1944 In-
ternational Sanitary Convention for Aerial
Navigation, the 17D vaccine was approved,
followed by the French vaccine, given by
scarification [59]. But neurologic reactions
with the French vaccine were becoming
more evident. An emergency vaccination
campaign in Nigeria in 1953 was associated
with multiple cases of encephalitis, and for
the first time, vaccine virus was recovered
from affected brain tissue [60]. A similar
cluster of encephalitis cases occurred in
Costa Rica and the Congo [44,61]. Sporadic
cases of encephalitis also were being re-
ported after the 17D vaccine, but almost all
in infants.
The Pasteur Institute in Paris had begun
experimenting with the 17D vaccine as early
as 1936. Acknowledging its lower but ade-
quate antigenicity vis-a-vis the French vac-
cines, the Institute eventually recommended
it as the preferred vaccine for use in areas
with appropriate technology [62]. Attempts
to use the 17D vaccine by scarification were
abandoned because of poor antibody pro-
duction [63,64]. The demise of the French
vaccine was only a matter of time, and by
1982, production of the French vaccine was
discontinued [65].
In 1962, alarm bells sounded again
when avian leukosis virus was detected in a
seed lot of 17D vaccine in England [66] and
in the United States shortly after [67], a find-
ing of potentially disastrous proportions.
These viruses, the cause of avian leukosis,
displayed oncogenic activity in animals.
They were widespread in the fowl popula-
tion and the eggs used for virus culture. Un-
doubtedly, thousands or millions of people
had been inadvertently inoculated with these
potentially oncogenic viruses.The challenge
was to eliminate the avian virus while keep-
ing additional passages of vaccine virus to a
minimum. In England, this was achieved by
incubating the vaccine with antibody against
avian virus, in the United States by ultrafil-
tration, and required only three and one
extra passages respectively [68,69]. In 1972,
the oncogenic issue was laid to rest with a
study of 2,659 vaccinated veterans who died
of cancer. Using matched controls, no evi-
dence of excess cancer in the vaccinees was
found [70].
Since 1982, the 17D vaccine, presumed
clear of all contamination and manufactured
from a small number of seed lots, has been
the only one in use. Further developments
have been of a more technical nature, such
as greater stabilization of the vaccine, allow-
ing a longer storage life [71]. The vaccines
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strains, the 17DD and 17D-204, originally
obtained from passage numbers 195 and
204, respectively, at the Rockefeller Insti-
tute. In 1985, the complete genome of the
virus was published, ushering in a new era
of research, both in the basic mechanisms of
virus reproduction and assessing individual
components for pathogenicity [72,73]. New
issues include a rising incidence of severe
viscerotropic disease after vaccination, most
often in elderly and thymectomized individ-
uals, and the use of the yellow fever vaccine
virus as a vehicle to introduce antigens of
other flaviviruses (such as dengue and
Japanese B viruses), so-called “chimeric”
vaccines [74].
CONCLUSION
The road to the current vaccine was
bumpy and sometimes convoluted. The
problems of attenuation of the virus in tissue
culture, its large scale manufacture in eggs,
and elimination of contaminants all pushed
thelimitsofscientificknowledgeofthetime.
For his efforts in extending these frontiers,
Theiler was awarded the Nobel Prize in
1950, after only three nominations (appar-
entlyalownumber)[75].Afterhislongserv-
ice at the Rockefeller Institute, he was
appointed professor of Epidemiology and
Public Health at Yale University Medical
School from 1964 to 1967, and he died in
1972.
The earlier dream of eliminating yellow
fever from the earth by mosquito control
died with the discovery of the jungle cycle.
Vaccination still provides an essential,
though often underutilized, mode of protec-
tion. World Health Organization programs
for the laboratory detection of yellow fever
outbreaks and the dispensation of vaccine
for both preventive and emergency uses (in
conjunction with the Global Alliance for
Vaccines and Immunization) are now in ef-
fect [76]. The modern vaccine, though not
perfect, plays a major role today in prevent-
ing and/or interrupting outbreaks of “yellow
jack,” once the scourge of so many commu-
nities.
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